GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Pretax Margin %

SILO Pharma (SILO Pharma) Pretax Margin % : -5,844.44% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. SILO Pharma's Pre-Tax Income for the three months ended in Dec. 2023 was $-1.05 Mil. SILO Pharma's Revenue for the three months ended in Dec. 2023 was $0.02 Mil. Therefore, SILO Pharma's pretax margin for the quarter that ended in Dec. 2023 was -5,844.44%.

The historical rank and industry rank for SILO Pharma's Pretax Margin % or its related term are showing as below:

SILO' s Pretax Margin % Range Over the Past 10 Years
Min: -5426.39   Med: 166.37   Max: 5890.14
Current: -5043.06


SILO's Pretax Margin % is ranked worse than
86.34% of 1032 companies
in the Biotechnology industry
Industry Median: -167.31 vs SILO: -5043.06

SILO Pharma Pretax Margin % Historical Data

The historical data trend for SILO Pharma's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SILO Pharma Pretax Margin % Chart

SILO Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,470.73 - 5,890.14 -5,426.39 -5,043.06

SILO Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,238.89 -5,033.33 -5,627.78 -3,666.67 -5,844.44

Competitive Comparison of SILO Pharma's Pretax Margin %

For the Biotechnology subindustry, SILO Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where SILO Pharma's Pretax Margin % falls into.



SILO Pharma Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

SILO Pharma's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-3.631/0.072
=-5,043.06 %

SILO Pharma's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.052/0.018
=-5,844.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SILO Pharma  (NAS:SILO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


SILO Pharma Pretax Margin % Related Terms

Thank you for viewing the detailed overview of SILO Pharma's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


SILO Pharma (SILO Pharma) Business Description

Traded in Other Exchanges
N/A
Address
560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632
SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.
Executives
Eric Weisblum director, officer: President and CCO 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz director 560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller director
Joel Alan Stone, director 1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps director C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand director, officer: Chairman and CEO 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd 10 percent owner P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats officer: VP of Business Development 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis director, officer: CFO 72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 72 POND ROAD, WOODBURY NY 11797